Education
About Us
Working with TipRanks
Follow Us
West Pharmaceutical Services, Inc. (WST)
NYSE:WST
Earnings Data
Report Date
Apr 23, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
1.68Last Year’s EPS
1.45Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a predominantly positive picture: strong cash flow generation, record annual sales above $3 billion, outsized growth in high value product components (HVP), margin and EPS expansion, and constructive initial guidance for 2026. Management acknowledged some near-term execution and market headwinds — including capacity constraints, a Q4 delivery device decline driven by a prior-year incentive, a temporary production disruption at a Contract Manufacturing site, the SmartDose divestiture, and an anticipated slowdown in GLP-1 growth versus 2025's pace. However, the positives (robust FCF improvement, strong HVP performance, gross margin expansion, clear pipeline from Annex 1 and GLP-1s, product launches and commercial progress, and constructive 2026 guidance) materially outweigh the listed lowlights.Company Guidance
Record Annual Sales and Organic Growth
Full-year 2025 net sales surpassed $3,000,000,000 with year-over-year organic growth of over 4%.
Strong Fourth Quarter Revenue Performance
Q4 2025 revenue of $850,000,000 exceeded expectations, increasing 7.5% reported and 3.3% organically versus prior year.
HVP Components Surge
High value product (HVP) components generated $390,000,000 in Q4 and grew 15.1% organically in the quarter; the HVP components business grew ~9% for the full year and represents 48% of company net sales.
Earnings and Margin Strength
Q4 adjusted EPS was $2.04, up 12.1% year-over-year and $0.20 above prior guidance midpoint; full-year adjusted EPS grew ~8% year-over-year. Gross margin in Q4 improved to 37.8%, up 130 basis points year-over-year.
Material Free Cash Flow and Operating Cash Flow Improvement
Full-year operating cash flow was $755,000,000 (up 15.5% YoY) and free cash flow was $469,000,000, up 70% YoY. Q4 free cash flow was $175,000,000 (more than double prior-year). The company ended the year with $791,000,000 in cash.
Lower Capital Intensity
Capital expenditures for 2025 were $286,000,000, down $91,000,000 year-over-year; 2026 CapEx guidance is $250,000,000 to $275,000,000 (targeting 6%–8% of sales).
2026 Guidance with Continued Growth Expectations
Full-year 2026 guidance: revenue $3,215,000,000 to $3,275,000,000 (reported growth 4.6%–6.5%; organic ~5%–7%), adjusted EPS $7.85 to $8.20 (double-digit growth at midpoint). Q1 2026 guidance: revenue $770,000,000 to $790,000,000 (organic 5%–7%); adjusted EPS $1.65 to $1.70 (up 13%–16%).
Commercial Progress, Product Launches and Strategic Actions
Launched West Synchrony prefillable syringe system (commercial launch and initial orders); commenced commercial drug handling production in Dublin; completed portfolio review and announced sale of SmartDose 3.5 mL business (expected to close midyear) as part of strategic repositioning.
Large, Visible Annex 1 Pipeline
Management highlighted a multiyear Annex 1 upgrade opportunity: ~6,000,000,000 components addressable, >700 Annex 1 projects initiated (over half completed), 65 projects completed in 2025 and ~325 underway — providing multi-year revenue runway.
WST Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
WST Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 12, 2026 | $246.16 | $243.61 | -1.04% |
Oct 23, 2025 | $276.53 | $306.73 | +10.92% |
Jul 24, 2025 | $226.73 | $278.39 | +22.78% |
Apr 24, 2025 | $217.41 | $209.85 | -3.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does West Pharmaceutical Services, Inc. (WST) report earnings?
West Pharmaceutical Services, Inc. (WST) is schdueled to report earning on Apr 23, 2026, Before Open (Confirmed).
What is West Pharmaceutical Services, Inc. (WST) earnings time?
West Pharmaceutical Services, Inc. (WST) earnings time is at Apr 23, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is WST EPS forecast?
WST EPS forecast for the fiscal quarter 2026 (Q1) is 1.68.
